Ticker history: CDXC became NAGE (Niagen Bioscience, Inc.) on . Earlier news and filings retain their original names and dates. View CDXC history.
What Changed
Price Move History
- Daily moves over 5%
- 19 252 sessions, November 13, 2025 to November 13, 2026
- Largest daily move
- -16.5% close of November 5, 2026
- 1-year change
- -70.5% closing prices, November 13, 2025 to November 13, 2026
- 1-month change
- -20% closing prices, October 13, 2026 to November 13, 2026
Company Description
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is a bioscience company in the healthcare sector focused on biotechnology, NAD+ (nicotinamide adenine dinucleotide) science, and healthy-aging research. The company describes itself as the global authority and a trusted pioneer in NAD+ discoveries, dedicated to advancing healthspan through precision science and NAD+-boosting solutions built around its patented ingredient Niagen® (nicotinamide riboside, or NR).
Core focus on NAD+ biology and healthy aging
According to multiple company disclosures and press releases, Niagen Bioscience concentrates on understanding and applying NAD+ biology. NAD+ is described as a vital coenzyme found in every cell of the human body, essential for cellular energy production, DNA repair, metabolism, and overall cellular health. The company highlights that NAD+ levels decline with age and exposure to everyday lifestyle stressors, and that this depletion is a key contributor to age-related changes in health and vitality. Niagen Bioscience positions its work as addressing this decline through NAD+ precursors, particularly nicotinamide riboside.
Niagen® and NAD+ precursor platform
At the center of Niagen Bioscience’s business is Niagen®, its patented form of nicotinamide riboside (NR). Company materials repeatedly describe Niagen as the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen is commercialized in both food-grade and pharmaceutical-grade forms and is protected by a robust patent portfolio that covers NR and other NAD+ precursors. The company reports that its intellectual property estate includes dozens of issued and pending patents worldwide, with a large concentration focused specifically on NR and its derivatives.
Niagen Bioscience has also disclosed that it acquired a comprehensive portfolio of existing patents covering NR and its salt forms from Queen’s University Belfast, consolidating ownership of core composition-of-matter and related patents underpinning NR production, composition, and commercial use. These patents include rights to multiple NR salt forms and methods of making NR and other NAD+ precursors across multiple jurisdictions.
Consumer products: Tru Niagen® and Tru Niagen® Beauty
Niagen Bioscience delivers Niagen as the principal dietary ingredient in its consumer supplement line Tru Niagen®. Company communications state that Tru Niagen is the number one NAD+ boosting oral supplement in the United States, based on revenue data from a large U.S. e-commerce marketplace over a defined historical period. Tru Niagen is positioned as a science-backed nutritional supplement for cellular health and healthy aging, available through the company’s direct-to-consumer website and through global retail and distribution partners.
The company has also launched Tru Niagen® Beauty, described as the first NAD+ skincare supplement in the U.S. featuring Niagen. Tru Niagen Beauty is presented as a cellular-first beauty product designed to support skin elasticity and the appearance of hair, skin, and nails. It combines Niagen with a blend of clinically studied ingredients such as astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E, with the stated goal of nourishing beauty from within while complementing core Tru Niagen products.
Clinical-grade offerings: Niagen Plus™ IV and injections
Beyond consumer supplements, Niagen Bioscience develops and commercializes pharmaceutical-grade Niagen® under the Niagen Plus™ brand. These offerings include intravenous (IV) and injectable Niagen products that are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and made available exclusively at clinics with a prescription. The company reports that Niagen IV and injections are offered at hundreds of clinics nationwide, including numerous iCRYO wellness centers, and are intended for individuals seeking NAD+-boosting therapies to support cellular health, recovery, performance, and healthy aging.
Company communications describe Niagen IV as a clinically validated intravenous solution for supporting NAD+ levels, and reference a pilot clinical study in which Niagen IV outperformed NAD+ IV on measures such as tolerability, infusion time, and increases in whole blood NAD+ levels. Niagen Bioscience contrasts Niagen with direct NAD+ supplementation, noting that NAD+ itself is not considered bioavailable in the same way and that oral or intravenous NAD+ has not been well studied in humans.
Research, clinical evidence, and scientific collaborations
Niagen Bioscience emphasizes its scientific orientation and research infrastructure. The company states that Niagen is supported by more than 40 peer-reviewed human clinical studies, over 500 published scientific papers, and more than 50 patents worldwide. It highlights collaborations with independent investigators from universities and research institutions around the globe, and notes that its team includes world-renowned scientists and advisors in fields such as metabolism, brain health, and aging.
The company has reported results from a randomized, double-blind, placebo-controlled clinical trial using Niagen in individuals with long COVID (post-acute sequelae of SARS-CoV-2 infection). According to the published summary, Niagen supplementation in this study significantly increased NAD+ levels and showed within-group improvements from baseline in measures such as fatigue, sleep quality, depression, and executive functioning, while between-group differences versus placebo were not statistically significant. Niagen Bioscience presents this as evidence that restoring NAD+ is a measurable biological response and a potential avenue for further research in conditions of metabolic and cellular stress.
Digital and educational platforms: AboutNAD®
In addition to products, Niagen Bioscience operates AboutNAD®, described as a centralized educational resource and research database focused on NAD+ biology. The platform curates peer-reviewed literature, scientific explainers, and expert perspectives on NAD+ and NAD+ precursors, with a particular emphasis on nicotinamide riboside. It offers categorized research, advanced search tools, and educational content aimed at consumers, clinicians, and researchers who want to understand the published science behind NAD+ and healthy aging.
Business activities and revenue drivers
Company filings and press releases indicate that Niagen Bioscience generates revenue through several related activities:
- Sales of Tru Niagen-branded consumer dietary supplements through direct-to-consumer channels and retail and distribution partners.
- Supply of food-grade Niagen as a raw material ingredient to manufacturers of consumer products.
- Commercialization of pharmaceutical-grade Niagen Plus IV and injectable products through U.S. FDA-registered 503B outsourcing facilities and clinic networks.
- Sales of natural product fine chemicals (phytochemicals) and related research and development services.
In investor communications, the company has also discussed e-commerce momentum, new business-to-business partnerships, and expansion of clinical distribution networks as contributors to its growth outlook.
Intellectual property and supply agreements
Niagen Bioscience’s strategy places significant emphasis on intellectual property protection around NAD+ precursors. The company’s patent portfolio covers NR, NR salt forms, and other NAD+ precursors, including composition-of-matter patents and methods of making these molecules. Through an assignment agreement with Queen’s University Belfast, Niagen Bioscience has become the sole owner of key NR patents that were previously jointly owned or licensed, and it has obtained a release from prior royalty and payment obligations under earlier agreements.
The company has also entered into a supply agreement under which a third-party manufacturer exclusively supplies nicotinamide-beta-riboside chloride (NRCL) to Niagen Bioscience, subject to defined specifications and minimum purchase commitments. The supplier is restricted from selling NRCL to other parties and must notify Niagen Bioscience of any new business inquiries relating to NRCL. The agreement includes provisions for potential future licensing of manufacturing patents under certain conditions.
Capital markets activity and shareholder programs
Niagen Bioscience is listed on NASDAQ under the ticker symbol NAGE. The company has disclosed a share repurchase program authorizing the repurchase of up to a specified dollar amount of its common stock over a multi-year period, with repurchases to be made at management’s discretion in accordance with applicable securities laws. The authorization may be modified, suspended, or terminated by the board of directors and does not obligate the company to repurchase a particular number of shares.
At its annual meeting, the company’s stockholders have approved amendments to its equity incentive plan to increase the number of shares available for issuance, as well as an employee stock purchase plan that allows eligible employees to acquire shares through payroll deductions at a discount to market price, subject to plan limits and terms.
Positioning within biotechnology and healthy-aging markets
Within the broader biotechnology and healthy-aging landscape, Niagen Bioscience presents itself as a company focused on translating cellular and metabolic research into practical NAD+-boosting products. Its activities span consumer health supplements, clinical-grade IV and injectable therapies, ingredient supply, and educational initiatives. The company’s emphasis on peer-reviewed science, clinical trials, and patent protection is central to how it describes its differentiation in the NAD+ category.
Stock Performance
Niagen Bioscience (NAGE) closed at $2.07 on November 13, 2026. Over the past 12 months, the price has lost 70.5%.
NAGE Metrics & Rankings
Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Niagen Bioscience has 10 recent news articles, with the latest published today. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include conferences, earnings, earnings date. View all NAGE news →
SEC Filings
Niagen Bioscience has filed 10 recent SEC filings, including 3 Form 4, 2 Form 10-Q, 2 Form 8-K, 1 Form SCHEDULE 13G. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all NAGE SEC filings →
Financial Highlights
Niagen Bioscience generated $129.4M in revenue in FY2025, retaining a 64.3% gross margin, operating income reached $16.3M (12.6% operating margin), and net income was $17.4M, reflecting a 13.4% net profit margin. Diluted earnings per share stood at $0.20. The company generated $13.5M in operating cash flow. The current ratio was 4.86, measuring current assets divided by current liabilities.
Upcoming Events
Southwest IDEAS presentation
Longevity Summit Presentation
ROTH Deer Valley meetings
StoneX one-on-one meetings
Share repurchase program expiry
Patent protection expiry
Niagen Bioscience has 6 upcoming scheduled events. The next event, "Southwest IDEAS presentation", is scheduled for November 19, 2026 (in 3 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the NAGE stock price.
Short Interest History
Short interest in Niagen Bioscience (NAGE) currently stands at 4.3 million shares, up 4.2% from the previous reporting period, representing 7.8% of the float. Since November 2025, short interest has decreased by 21.2%.
Days to Cover History
Days to cover for Niagen Bioscience (NAGE) currently stands at 8.9 days, up 43.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 26.7%. Across the settlements charted above, it has ranged from 2.2 to 11.3 days.
NAGE Company Profile & Sector Positioning
Niagen Bioscience (NAGE) operates in the Packaged Foods industry within the broader Consumer Defensive sector and is listed on the NASDAQ.
Investors comparing NAGE often look at related companies in the same sector, including Nature's Sunshine Products Inc. (NATR), BRC Inc. (BRCC), USANA Health Sciences Inc (USNA), Oatly Group AB (OTLY), and Beyond Meat, Inc. (BYND). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate NAGE's relative position within its industry.